JAK2 and acute lymphoblastic leukemia: Genomic alterations activating kinase signaling were identified in 91% of the Ph-like ALL patients (N = 156) including ABL-class fusions, rearrangements of JAK2 or CRLF2, genetic alterations including IL7R and FLT3, and Ras pathway mutations [31].